Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population-Reference-Cited by-同舟云学术

Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population

Published:2016-10-28 Issue:5 Volume:32 Page:609-617
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Kitagawa Fumihiko,Ishii Junnichi,Hiramitsu Shinya,Takahashi Hiroshi,Okuyama Ryuunosuke,Kawai Hideki,Muramatsu Takashi,Harada Masahide,Motoyama Sadako,Naruse Hiroyuki,Matsui Shigeru,Sarai Masayoshi,Hayashi Mutsuharu,Watanabe Eiichi,Izawa Hideo,Ozaki Yukio

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00380-016-0912-0.pdf

Reference29 articles.

1. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J 76:2104–2111

2. Tagaya M, Yoshikawa D, Sugishita Y, Yamauchi F, Ito T, Kameda T, Yoshinaga M, Mukaide D, Fujiwara W, Yokoi H, Hayashi M, Watanabe E, Ishii J, Ozaki Y, Izawa H (2016) Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution. Heart Vessels 31:957–962

3. Miyamoto K, Aiba T, Arihiro S, Watanabe M, Kokubo Y, Ishibashi K, Hirose S, Wada M, Nakajima I, Okamura H, Noda T, Nagatsuka K, Noguchi T, Anzai T, Yasuda S, Ogawa H, Kamakura S, Shimizu W, Miyamoto Y, Toyoda K, Kusano K (2015) Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Heart Vessels. doi: 10.1007/s00380-015-0725-6

4. Trujillo T, Dobesh PP (2014) Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs 74:1587–1603

5. Yasaka M, Lip GYH (2014) Stroke prevention in Asian patients with atrial fibrillation. Stroke 45:1608–1609

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence;Journal of Thrombosis and Thrombolysis;2023-02-06

2. Increased Prevalence of Elevated D-Dimer Levels in Patients on Direct Oral Anticoagulants: Results of a Large Retrospective Study;Frontiers in Cardiovascular Medicine;2022-03-31

3. Blood Coagulation Changes With or Without Direct Oral Anticoagulant Therapy Following Transcatheter Aortic Valve Implantation;The American Journal of Cardiology;2021-05

4. Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation;The American Journal of Cardiology;2020-12

5. Combination therapy with an Xa inhibitor and antihypertensive agent improved anticoagulant activity in patients with nonvalvular atrial fibrillation: the hypertension and atrial fibrillation treated by rivaroxaban for the morning and night with sYnergy with calcium antagonists (HARMONY) study;Clinical and Experimental Hypertension;2019-09-21